Obesity Clinical Trial
— ESGORTOfficial title:
An Open-label, Randomized, Controlled Clinical Trial on the Effects of Endoscopic Sleeve Gastroplasty on Weight, Metabolic Risk Factors, Quality of Life, Satiety, Gastrointestinal Motility and Gut Microbiota
NCT number | NCT04200144 |
Other study ID # | 2837 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 4, 2020 |
Est. completion date | December 2, 2025 |
This is an interventional, open-label, randomized (2:1), standard medical therapy-controlled trial. Subjects in the standard therapy group will be given the opportunity to undergo the active endoscopic treatment after 6 months of follow up (open label extension) if they will not achieve an adequate result on body weight. All patients will be followed until the planned end of the study after 36 months from the ESG procedure. To study the effects of endoscopic gastroplasty on weight, metabolic risk factors, quality of life, satiety, gastrointestinal motility and gut microbiota compared to standard medical treatment control group. Primary endpoint: - Total body weight loss (%) Secondary endpoints: - Metabolic risk factors (e.g. lipid profile) and anthropometric measurements (e.g hip and waist circumference) - Body composition - Quality of life - Gastroesophageal reflux disease - Non-Alcoholic Fatty Liver Disease (NAFLD) - Non- Alcoholic-Steato-Hepatitis (NASH) - Satiety - Gut microbiota Exploratory endpoints: - Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin - Gastrointestinal motility
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2, 2025 |
Est. primary completion date | December 2, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: The participants have to fulfill the following criteria for participating in the study: - Age 20 to 65 years - BMI between 30 to 45 kg/m2 - Willingness to participate in the study and ability to comply and understand the study protocol Exclusion Criteria: Active gastric ulcer during the last 6 months - Organic or motility disorder of the stomach and / or esophagus - Anticoagulant treatment - Previous bariatric surgery or any other type of surgery of the esophagus, stomach and duodenum - Ongoing or active malignancy during the last 5 years - Myocardial infarction during the past 6 months or/and heart failure class III or IV according to the New York Heart association's classification - Drug or alcohol abuse - Bulimic or binge eating pattern - Continuous glucocorticoid or anti-inflammatory treatment - Uncontrolled thyroid disease - Pregnancy, breastfeeding - Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study - Hiatal hernia > 5 cm - Currently participating in other study - Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total body weight loss | Total body weight loss (%) measurement in kg and BMI | 12 months | |
Primary | Total body weight loss | Total body weight loss (%) measurement in kg and BMI | 36 months | |
Secondary | Non-Alcoholic Fatty Liver Disease evaluation | Non-Alcoholic Fatty Liver Disease | 12 months | |
Secondary | Non- Alcoholic-Steato-Hepatitis evaluation | Non- Alcoholic-Steato-Hepatitis | 12 months | |
Secondary | Gut microbiota characterization | Gut microbiota | 6 months | |
Secondary | Evaluation for Gastroesophageal reflux disease | Gastroesophageal reflux disease | 12, 24, 36 months | |
Secondary | Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin dosages | Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin | Baseline and 6 months | |
Secondary | performing of gastric emptying scintigraphy for gastrointestinal motility | Gastrointestinal motility evaluation | Baseline and six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |